SOUTH
SAN FRANCISCO, Calif., Nov. 12,
2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.
(Nasdaq: RIGL), a commercial stage biotechnology company focused on
hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial
officer, will present a company overview at the Jefferies London
Healthcare Conference on Tuesday, November
19, at 9:30 am GMT
(4:30 am EST).
To access the live webcast or archived recording, visit the
Investor Relations section of the company's website at
www.rigel.com. Please connect to Rigel's website prior to the start
of the live webcast to allow for any software downloads.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL)
is a biotechnology company dedicated to discovering, developing and
providing novel therapies that significantly improve the lives of
patients with hematologic disorders and cancer. Founded in 1996,
Rigel is based in South San Francisco,
California. For more information on Rigel, the Company's
marketed products and pipeline of potential products,
visit www.rigel.com.
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
646.461.6387
david.rosen@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rigel-to-present-at-the-jefferies-london-healthcare-conference-302302060.html
SOURCE Rigel Pharmaceuticals, Inc.